[Form 4] LifeMD, Inc. Insider Trading Activity

Rhea-AI Filing Summary

LifeMD, Inc. (LFMD) director Calum Archibald MacRae filed a Form 4 disclosing a non‑derivative grant of 22,365 restricted shares on 10/02/2025. The filing shows 38,865 total shares beneficially owned by the reporting person after the transaction. The restricted shares have a vesting condition: they vest on 06/01/2026. The transaction was reported on 10/06/2025 with a reported price of $0, consistent with a grant rather than an open‑market purchase.

Positive

• 22,365 restricted shares granted increases director's alignment with shareholders
• Total beneficial ownership 38,865 shares shows meaningful insider stake

Negative

• Restricted shares vest on 06/01/2026, so economic ownership is delayed
• Filing shows $0 price, indicating a grant rather than insider purchase (no immediate cash investment)

Insights

Corporate Governance Analyst

Director received a restricted share grant that increases reported ownership and aligns incentives through mid‑2026 vesting.

The grant of 22,365 restricted shares increases the director's reported stake to 38,865 shares, which can strengthen alignment between management and shareholders by tying compensation to future share performance.

Key dependencies include the vesting date of 06/01/2026 and any company performance or service conditions that must be met for vesting; the filing notes only the vesting date. Monitor whether any additional restrictions or forfeiture conditions are disclosed in other filings before 06/01/2026.

Insider Transactions Specialist

The Form 4 reports a grant (price listed as $0) rather than an open‑market trade, indicating compensation issuance.

The transaction code and a $0 price indicate a compensatory issuance of restricted stock on 10/02/2025, not a purchase. Such grants are common for directors and reflect non‑cash compensation.

Short‑term monitoring should focus on subsequent filings for any sales or additional grants and confirmation of vesting occurrence on 06/01/2026. No derivative securities were reported in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MACRAE CALUM ARCHIBALD

(Last) (First) (Middle)

C/O LIFEMD, INC.

236 FIFTH AVENUE, 4TH FLOOR

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LifeMD, Inc. [ LFMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/02/2025		A		22,365(1)	A	$0	38,865	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The grant of restricted shares vests on June 1, 2026.

	/s/ Calum Archibald MacRae	10/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did LifeMD (LFMD) director Calum Archibald MacRae report on Form 4?

The director reported a grant of 22,365 restricted shares on 10/02/2025, bringing total beneficial ownership to 38,865 shares, with vesting on 06/01/2026.

Does the Form 4 show a purchase or a grant for LFMD insider activity?

The transaction is reported with a price of $0, which indicates a compensatory grant (restricted shares), not an open‑market purchase.

When do the newly reported restricted shares vest?

The restricted shares are scheduled to vest on 06/01/2026 according to the filing.

How many LFMD shares does the reporting person own after the transaction?

The Form 4 reports 38,865 shares beneficially owned following the reported grant.

Were any derivative securities reported in this Form 4 for LFMD?

No derivative securities (options, warrants, or convertible instruments) were reported in Table II of this filing.